We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-2.7%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$849M
AUM Growth
-$49.5M
Cap. Flow
-$2.98M
Cap. Flow %
-0.35%
Top 10 Hldgs %
99.98%
Holding
12
New
–
Increased
3
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.2M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$5.85M
3
MRSN
Mersana Therapeutics
MRSN
+$5.4M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30B
$182M 21.47%
643,000
– –
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$15.9B
$132M 15.58%
928,100
– –
ALKS icon
3
Alkermes
ALKS
$8.22B
$130M 15.26%
7,825,000
– –
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$696M
$126M 14.87%
14,040,000
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$91.3M 10.75%
797,740
+54,240
+7% +$5.85M
INVA icon
6
Innoviva
INVA
$1.55B
$67M 7.89%
6,414,000
– –
MRSN
7
DELISTED
Mersana Therapeutics
MRSN
$52.8M 6.22%
113,480
+10,680
+10% +$5.4M
ICPT
8
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$49.8M 5.86%
1,201,000
– –
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.28B
$16.7M 1.97%
4,861,000
+3,786,000
+352% +$16.2M
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
$951K 0.11%
185,185
– –
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$166K 0.02%
1,000
– –
ABBV icon
12
AbbVie
ABBV
$443B
– –
-310,150
Closed -$30.4M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sarissa Capital Management held 12 positions worth $849M, down 5.5% from $899M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management's Q3 2020 filing shows 3 increased and 1 closed positions. The largest sale was AbbVie, an estimated $30.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sarissa Capital Management added most to BioCryst Pharmaceuticals in Q3 2020, an estimated $16.2M increase.
  • Sarissa Capital Management fully exited AbbVie in Q3 2020, selling an estimated $30.4M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $849M portfolio in Q3 2020.
  • Sarissa Capital Management opened 0 new positions and closed 1 in Q3 2020.
  • Sarissa Capital Management's portfolio value fell 5.5% quarter-over-quarter to $849M.

Based on Sarissa Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.